What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.06%
Annual Rate
CNY 0.47Paid annual
Payout Ratio
26.6%Sustainable
Payback Period
98.9 yr
Last Ex-Dividend
May 28, 2026
The reported statements, read against the company's own industry.
What stands out
Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
5.54BCNY
826.69M · vs all stocks (USD)
Updated Sep 19, 2026
Trailing P/E
25.34x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Revenue (TTM)
1.38BCNY
205.71M · vs all stocks (USD)
Updated Sep 19, 2026
Profit Margin
16.02%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Beta
0.4320x
vs all stocks
Updated Sep 19, 2026
52-Week Change
-27.61%
vs all stocks
Updated Sep 19, 2026
Market Capitalization
5.54BCNY
826.69M · vs all stocks (USD)
Updated Sep 19, 2026
Enterprise Value
3.00BCNY
447.69M · vs all stocks (USD)
Updated Sep 19, 2026
Trailing P/E
25.34x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Forward P/E
15.79x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Price to Sales (TTM)
4.08x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Price to Book (MRQ)
1.81x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Enterprise to Revenue
2.18x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Enterprise to EBITDA
10.52x
vs Medical Instruments & Supplies peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 9.17×.Updated Sep 19, 2026
Gross Margin
52.63%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Profit Margin
16.02%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Operating Margin
24.83%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Return on Assets (TTM)
4.80%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Return on Equity (TTM)
7.58%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Revenue (TTM)
1.38BCNY
205.71M · vs all stocks (USD)
Updated Sep 19, 2026
Revenue per Share (TTM)
11.08CNYUpdated Sep 19, 2026
Quarterly Revenue Growth
63.00%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Gross Profit (TTM)
732.39MCNY
109.29M · vs all stocks (USD)
Updated Sep 19, 2026
EBITDA (TTM)
327.22MCNY
48.83M · vs all stocks (USD)
Updated Sep 19, 2026
Net Income (TTM)
220.89MCNY
32.96M · vs all stocks (USD)
Updated Sep 19, 2026
Quarterly Earnings Growth (YoY)
48.40%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Operating Cash Flow (TTM)
173.63MCNY
25.91M · vs all stocks (USD)
Updated Sep 19, 2026
Levered Free Cash Flow (TTM)
95.07MCNY
14.19M · vs all stocks (USD)
Updated Sep 19, 2026
Trailing Annual Dividend Rate
0.4714CNYUpdated Sep 19, 2026
Trailing Annual Dividend Yield
1.06%
vs all stocks
Updated Sep 19, 2026
Payout Ratio
26.57%
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Minority Interest (Equity)
12.66MCNYFY2025 · Dec 31, 2025
Revenue
1.16BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
545.71MCNYFY2025 · Dec 31, 2025
Gross Profit
613.70MCNYFY2025 · Dec 31, 2025
Operating Income
241.65MCNY
36.06M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
261.36MCNYFY2025 · Dec 31, 2025
Income Tax Expense
30.10MCNYFY2025 · Dec 31, 2025
Net Income
231.26MCNYFY2025 · Dec 31, 2025
EBIT
266.33MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
309.57MCNYFY2025 · Dec 31, 2025
Research & Development
139.12MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
156.81MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
12.21MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
14.89MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
4.97MCNYFY2025 · Dec 31, 2025
EPS (Basic)
1.81CNYFY2025 · Dec 31, 2025
EPS (Diluted)
1.81CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
124.38MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
124.38MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
231.26MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-5.60MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
74.00MCNYFY2025 · Dec 31, 2025
Free Cash Flow
41.93MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.07BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
231.26MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
10.17MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-135.35MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-32.07MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-32.07MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-4.58BCNYFY2025 · Dec 31, 2025
Sale of Investments
5.39BCNYFY2025 · Dec 31, 2025
Other Investing Activity
36.93MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
819.22MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
447.31MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-706.47MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-41.94MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-39.28MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-340.38MCNYFY2025 · Dec 31, 2025
Shares Outstanding
125.28MSharesUpdated Sep 19, 2026
Float Shares
57.09MSharesUpdated Sep 19, 2026
% Held by Insiders
53.32%
vs all stocks
Updated Sep 19, 2026
% Held by Institutions
11.24%
vs all stocks
Updated Sep 19, 2026
Total Cash (MRQ)
2.62BCNY
391.40M · vs all stocks (USD)
Updated Sep 19, 2026
Total Cash per Share (MRQ)
21.25CNYUpdated Sep 19, 2026
Total Debt (MRQ)
192.64MCNY
28.75M · vs all stocks (USD)
Updated Sep 19, 2026
Total Debt to Equity (MRQ)
0.0627x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Current Ratio (MRQ)
6.29x
vs Medical Instruments & Supplies peers
Updated Sep 19, 2026
Book Value per Share (MRQ)
24.78CNYUpdated Sep 19, 2026
Total Assets
3.38BCNY
505.11M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
3.06BCNYFY2025 · Dec 31, 2025
Total Liabilities
341.39MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
325.00MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
3.15MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
338.24MCNYFY2025 · Dec 31, 2025
Cash
1.06BCNYFY2025 · Dec 31, 2025
Cash Equivalents
5.75MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.07BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
1.52BCNYFY2025 · Dec 31, 2025
Accounts Receivable
241.77MCNYFY2025 · Dec 31, 2025
Inventory
115.79MCNYFY2025 · Dec 31, 2025
Accounts Payable
138.67MCNYFY2025 · Dec 31, 2025
Short-term Debt
81.18MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
24.97MCNYFY2025 · Dec 31, 2025
Long-term Debt
2.83MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
89.60MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.18BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
3.04BCNY
454.17M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
44.28MCNYFY2025 · Dec 31, 2025
52-Week Low
37.52CNYUpdated Sep 19, 2026
52-Week High
71.40CNYUpdated Sep 19, 2026
52-Week Change
-27.61%
vs all stocks
Updated Sep 19, 2026
Beta
0.4320x
vs all stocks
Updated Sep 19, 2026
50-Day MA
45.82CNYUpdated Sep 19, 2026
200-Day MA
50.42CNYUpdated Sep 19, 2026
Avg 10-Day Volume
1.40MSharesUpdated Sep 19, 2026
Avg 30-Day Volume
2.02MSharesUpdated Sep 19, 2026
Diluted EPS (TTM)
1.77CNYUpdated Sep 19, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Debt has fallen for four years while the share count rose over eight.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.63Receivables vs revenue divergence: 6.71
Financial Health
Altman Z-Score 11.79: safe zoneNotable
Altman Z-Score: 11.79
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.